Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ISC: Stroke Trial Halted when Ticlopidine Fails to Outperform Aspirin in African Americans By Charlene Laino Special to DG News PHOENIX, AZ -- February 18, 2003 -- The first prospective randomized double blind study to exclusively enroll African American patients who had suffered an ischemic stroke was halted prematurely when ticlopidine hydrochloride was found to be no more effective than aspirin at preventing recurrent stroke, myocardial infarction and vascular death, U.S. researchers report. "We were surprised ticlopidine did not outperform aspirin in the primary end point, which was a composite measure of vascular death, myocardial infarction or recurrent stroke," said investigator Phillip B. Gorelick, MD, of the Center for Stroke Research at Rush Medical College, Chicago, Illinois, United States. Dr. Gorelick presented the results here on February 15th at the 28th International Stroke Conference. Although stroke disproportionately affects African Americans, black patients have been underrepresented in stroke clinical trials, he said. The African American Antiplatelet Stroke Prevention Study was an investigator-initiated trial using an intention-to-treat analysis to compare the effectiveness and safety of 500 mg of ticlopidine hydrochloride daily with 650 mg of aspirin daily in African Americans. From 1995 to 2001, They enrolled 1,809 African Americans between 7 and 90 days of non-cardioembolic ischemic stroke. Eighty-five percent of patients had hypertension, 42% had high cholesterol levels and 42% were diabetic, Dr. Gorelick said. Most had a body-mass index of 30 or greater, and 66% had bilunar infarcts. The researchers utilized 2-sided testing procedures and 80% power to detect a 30% risk reduction of the primary outcome end point, he said. After extensive review of the interim analysis results, completed in Spring 2002, the National Institutes of Health-appointed Patient and Safety Monitoring Board decided to halt the blinded phase of the study, he reported. The reason: Ticlopidine did not perform as well as aspirin (p=0.08), Dr. Gorelick said. "The analysis showed ticlopidine would have less than 1% efficacy so all patients were turned over for open-label aspirin," he added. Despite the disappointing results, Dr. Gorelick said the findings offer important lessons that will be useful for planning and conducting future stroke prevention studies in African Americans and other high-risk groups, and will help to clarify the role of ticlopidine and aspirin in prevention of recurrent stroke. The National Institute of Neurological Disorders and Stroke sponsored the trial. [Study title: African American Antiplatelet Stroke Prevention Study (Aaasps): Main Phase Efficacy And Safety Results Abstract 99] E-mail this page to a friend or colleague! To print, use this version